TY - JOUR
T1 - Dose-Response Relationship between Intravitreal Injections and Retinal Nerve Fiber Layer Thinning in Age-Related Macular Degeneration
AU - Wang, Liang
AU - Swaminathan, Swarup S.
AU - Yang, Jin
AU - Barikian, Anita
AU - Shi, Yingying
AU - Shen, Mengxi
AU - Jiang, Xiaoshuang
AU - Feuer, William
AU - Gregori, Giovanni
AU - Rosenfeld, Philip J.
N1 - Funding Information:
Research supported by grants from Carl Zeiss Meditec, Inc. (Dublin, CA), the Salah Foundation, the National Eye Institute Center Core Grant (P30EY014801), and Research to Prevent Blindness (unrestricted grant) to the Department of Ophthalmology, University of Miami Miller School of Medicine. The funding organization had no role in the design or conduct of this research. Obtained funding: Rosenfeld
Funding Information:
Research supported by grants from Carl Zeiss Meditec, Inc. (Dublin, CA), the Salah Foundation, the National Eye Institute Center Core Grant ( P30EY014801 ), and Research to Prevent Blindness (unrestricted grant) to the Department of Ophthalmology, University of Miami Miller School of Medicine. The funding organization had no role in the design or conduct of this research.
Publisher Copyright:
© 2020 American Academy of Ophthalmology
PY - 2021/7
Y1 - 2021/7
N2 - Purpose: To determine if multiple intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors for unilateral exudative age-related macular degeneration (eAMD) are associated with thinning of the retinal nerve fiber layer (RNFL), we compared RNFL thickness measurements from the injected eye with that of the fellow eye with nonexudative age-related macular degeneration (neAMD). Design: Retrospective, cross-sectional study. Participants: Patients undergoing anti-VEGF therapy for unilateral eAMD. Methods: Patients receiving anti-VEGF therapy secondary to eAMD in 1 eye with neAMD in their fellow eye were identified. Patients with a known diagnosis of glaucoma were excluded. Spectral domain OCT measurements of the peripapillary RNFL thickness from both eyes were performed and compared. The differences in the RNFL thickness measurements between eyes were correlated with the number of injections and the duration of therapy. Main Outcome Measures: Correlation between the number of anti-VEGF injections and peripapillary RNFL thinning. Results: A total of 108 eyes of 54 patients were evaluated in this study. The average peripapillary RNFL thickness measurements of the injected eye and fellow eye were 87.3 ± 9.6 μm and 89.0 ± 7.5 μm, respectively (P = 0.055). The RNFL thickness difference (fellow eye minus injected eye) was significantly correlated with the number of injections (r = 0.40, P = 0.002) and months of injections (r = 0.38, P = 0.005). The relationship between the difference in the RNFL thickness and the number of injections had a nonlinear dose-response relationship that became apparent after approximately 30 injections and 50 months of injections. Conclusions: The difference in RNFL thickness measurements between injected eyes and uninjected fellow eyes was largely within the reported normal limits for interocular differences between healthy eyes. Nevertheless, there was a dose-response relationship between RNFL thinning and number of injections among patients receiving a greater number of injections, suggesting that anti-VEGF injections may have a modest effect on the RNFL thickness after several years of therapy in eyes requiring more anti-VEGF injections; however, we cannot exclude that the RNFL thinning may be secondary to active age-related macular degeneration (AMD) disease progression in both eyes.
AB - Purpose: To determine if multiple intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors for unilateral exudative age-related macular degeneration (eAMD) are associated with thinning of the retinal nerve fiber layer (RNFL), we compared RNFL thickness measurements from the injected eye with that of the fellow eye with nonexudative age-related macular degeneration (neAMD). Design: Retrospective, cross-sectional study. Participants: Patients undergoing anti-VEGF therapy for unilateral eAMD. Methods: Patients receiving anti-VEGF therapy secondary to eAMD in 1 eye with neAMD in their fellow eye were identified. Patients with a known diagnosis of glaucoma were excluded. Spectral domain OCT measurements of the peripapillary RNFL thickness from both eyes were performed and compared. The differences in the RNFL thickness measurements between eyes were correlated with the number of injections and the duration of therapy. Main Outcome Measures: Correlation between the number of anti-VEGF injections and peripapillary RNFL thinning. Results: A total of 108 eyes of 54 patients were evaluated in this study. The average peripapillary RNFL thickness measurements of the injected eye and fellow eye were 87.3 ± 9.6 μm and 89.0 ± 7.5 μm, respectively (P = 0.055). The RNFL thickness difference (fellow eye minus injected eye) was significantly correlated with the number of injections (r = 0.40, P = 0.002) and months of injections (r = 0.38, P = 0.005). The relationship between the difference in the RNFL thickness and the number of injections had a nonlinear dose-response relationship that became apparent after approximately 30 injections and 50 months of injections. Conclusions: The difference in RNFL thickness measurements between injected eyes and uninjected fellow eyes was largely within the reported normal limits for interocular differences between healthy eyes. Nevertheless, there was a dose-response relationship between RNFL thinning and number of injections among patients receiving a greater number of injections, suggesting that anti-VEGF injections may have a modest effect on the RNFL thickness after several years of therapy in eyes requiring more anti-VEGF injections; however, we cannot exclude that the RNFL thinning may be secondary to active age-related macular degeneration (AMD) disease progression in both eyes.
KW - Retinal nerve fiber layer thickness
KW - age-related macular degeneration
KW - anti-vascular endothelial growth factor
KW - optical coherence tomography
UR - http://www.scopus.com/inward/record.url?scp=85097459239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097459239&partnerID=8YFLogxK
U2 - 10.1016/j.oret.2020.10.004
DO - 10.1016/j.oret.2020.10.004
M3 - Article
C2 - 33045458
AN - SCOPUS:85097459239
VL - 5
SP - 648
EP - 654
JO - Ophthalmology Retina
JF - Ophthalmology Retina
SN - 2468-7219
IS - 7
ER -